Benitec Biopharma (BNTC) Interest Expenses (2019 - 2025)

Benitec Biopharma (BNTC) has 7 years of Interest Expenses data on file, last reported at $14.8 million in Q4 2025.

• For the quarter ending Q4 2025, Interest Expenses fell 99.86% year-over-year to $14.8 million; the trailing twelve-month figure through Dec 2025 stood at $14.8 million (down 99.86% YoY), and the FY2025 full-year result was $7.7 billion, up 229.87% from the prior year.
• Interest Expenses fell to $14.8 million in Q4 2025, from $17.4 billion in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $17.4 billion in Q3 2025 to a low of $8000.0 in Q1 2021.
• A 5-year average of $2.4 billion and a median of $6.4 million in 2023 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses surged 1420480.41% in 2024 and sank 99.98% in 2025, its largest moves.
• Tracing BNTC's Interest Expenses over 5 years: stood at $152000.0 in 2021, then soared by 378.29% to $727000.0 in 2022, then jumped by 1451.99% to $11.3 million in 2023, then surged by 92138.5% to $10.4 billion in 2024, then sank by 99.86% to $14.8 million in 2025.
• Business Quant data shows BNTC's Interest Expenses at $14.8 million in Q4 2025, $17.4 billion in Q3 2025, and $356000.0 in Q2 2025.